Pulmonary Disease Clinical Trial
Official title:
Hydroxychloroquine or Hydroxychloroquine Associated With Azithromycin for Inpatients With Moderate or Severe Lung Disease Due to SARS-CoV-2 (COVID-19)
The Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV2) has been identified in Wuhan, China, which causes severe pulmonary complications and flu syndrome, which has spread rapidly to all continents. Approximately 25% of hospitalized patients require treatment in intensive care units and 10% require mechanical ventilation. The diagnosis is made by the molecular polymerase chain reaction test. However, diagnostic tests are limited. The clinical care of the patient with COVID-19 is similar to that of patients with severe infectious respiratory complications, consisting of support and oxygen supplementation. Several medications have been tested as remdesivir, a pro-drug nucleoside, which acts by inhibiting viral RNA transcription, although a recently published study has shown no benefit. China recently approved the use of favipiravir, an antiviral used for influenza, as an experimental therapy for COVID-19. Hydroxychloroquine is a drug with great potential treatment, as it can inhibit the pH-dependent steps of replication of various viruses, with a potent effect on SARS-CoV infection and spread. In this way, the present study will evaluate the safety and efficacy of the hydroxychloroquine in patients with symptomatic SARS-Cov2.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Recruiting |
NCT06088485 -
The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
|
||
| Terminated |
NCT03309358 -
A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis
|
Phase 1 | |
| Active, not recruiting |
NCT02504697 -
DECAMP-2: Screening of Patients With Early Stage Lung Cancer or at High Risk for Developing Lung Cancer
|
||
| Completed |
NCT01443845 -
Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)
|
Phase 4 | |
| Terminated |
NCT00524095 -
Bronchiectasis in Chronic Obstructive Pulmonary Disease (COPD) Patients: Role of Prophylaxis
|
Phase 2 | |
| Completed |
NCT00210249 -
Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment
|
||
| Completed |
NCT00023114 -
p450 Mediated Lung Toxicity
|
N/A | |
| Recruiting |
NCT06056882 -
Simultaneous CLE Guided Crybiopsy in Patients With Pulmonary Nodules
|
||
| Completed |
NCT03994848 -
Incentive Spirometry Prehabilitation Study
|
N/A | |
| Completed |
NCT00366509 -
Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
|
||
| Withdrawn |
NCT05100160 -
Gabapentin for the Reduction of Opiate Use Following Pulmonary Resection (GROUP Trial)
|
Phase 3 | |
| Completed |
NCT03229473 -
Fall Risk Assessment in COPD
|
||
| Recruiting |
NCT04767074 -
A Non-pharmacological Cough Control Therapy
|
N/A | |
| Not yet recruiting |
NCT03899298 -
Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions
|
Phase 1 | |
| Completed |
NCT04996693 -
On Dose Efficiency of Modern CT-scanners in Chest Scans
|
N/A | |
| Recruiting |
NCT04996173 -
Cryospray Therapy Versus Standard of Care for Benign Airway Stenosis (CryoStasis)
|
N/A | |
| Completed |
NCT04601545 -
The Virtual Reality Therapy as a Pulmonary Rehabilitation Supporting Method
|
N/A | |
| Recruiting |
NCT03937583 -
Screening for Cancer in Patients With Unprovoked VTE
|
Phase 4 | |
| Recruiting |
NCT02862418 -
Imaging of Lungs With a New Type of Magnetic Resonance Imaging (MRI) Called UTE (Ultrashort Echo Time)
|